A diversity of SERCA Ca2+ pump inhibitors

Francesco Michelangeli, JM East

Research output: Contribution to journalArticle

93 Citations (Scopus)


The SERCA (sarcoplasmic/endoplasmic reticulum Ca2+-ATPase) is probably the most extensively studied membrane protein transporter. There is a vast array of diverse inhibitors for the Ca2+ pump, and many have proved significant in helping to elucidate both the mechanism of transport and gaining conformational structures. Some SERCA inhibitors such as thapsigargin have been used extensively as pharmacological tools to probe the roles of Ca2+ stores in Ca2+ signalling processes. Furthermore, some inhibitors have been implicated in the cause of diseases associated with endocrine disruption by environmental pollutants, whereas others are being developed as potential anticancer agents. The present review therefore aims to highlight some of the wide range of chemically diverse inhibitors that are known, their mechanisms of action and their binding location on the Ca2+ ATPase. Additionally, some ideas for the future development of more useful isoform-specific inhibitors and anticancer drugs are presented.
Original languageEnglish
Pages (from-to)789-797
Number of pages9
JournalBiochemical Society Transactions
Publication statusPublished - 1 Jun 2011


  • sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA)
  • calcium pump inhibitor
  • calcium signalling
  • anticancer drug
  • Ca2+-ATPase


Dive into the research topics of 'A diversity of SERCA Ca2+ pump inhibitors'. Together they form a unique fingerprint.

Cite this